phasebio is a clinical-stage biopharmaceutical company developing novel drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. the company's proprietary discovery platform technology uses recombinant elastin-like polypeptide (elp) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. the resulting compounds are tuned for a specific rate of absorption, thereby increasing efficacy and reducing side effects. phasebio has completed several clinical trials of products in its portfolio. these include a phase 2b clinical trial with the glp-1 receptor agonist pb1023 for the treatment of hyperglycemia associated with type 2 diabetes; two phase 1 trials with pb1046, a long acting vasoactive intestinal peptide – the first delivered via subcutaneous injection and the second intravenously; and a phase 1 trial of pe0139, a once weekly basal insulin. pb1046 has exciting potential for us
Company profile
Ticker
PHASQ
Exchange
Website
CEO
Jonathan Mow
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DT BIOSCIENCES INC, Phase Biosciences Inc
SEC CIK
Corporate docs
IRS number
30375697
PHASQ stock data
Latest filings (excl ownership)
NT 10-K
Notice of late annual filing
2 Apr 24
8-K
Entry into a Material Definitive Agreement
12 Mar 24
8-K
Other Events
29 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
8-K
Departure of Directors or Certain Officers
3 Oct 23
8-K
Other Events
27 Sep 23
8-K
Other Events
25 Aug 23
NT 10-Q
Notice of late quarterly filing
25 Aug 23
8-K
Other Events
30 Jun 23
8-K
Other Events
30 May 23
Latest ownership filings
4
den Broek Richard van
19 May 23
4
Clay Thorp
19 May 23
4
William D. Humphries
19 May 23
4
EDMUND HARRIGAN
19 May 23
4
Alex Sapir
19 May 23
4
Caroline M Loewy
19 May 23
4
Nancy J Hutson
19 May 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G/A
Rock Springs Capital Management LP
14 Feb 23
SC 13G/A
Avidity Partners Management LP
14 Feb 23
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.80 mm | 7.80 mm | 7.80 mm | 7.80 mm | 7.80 mm | 7.80 mm |
Cash burn (monthly) | 3.63 mm | 4.72 mm | 8.44 mm | 9.88 mm | 3.47 mm | 4.95 mm |
Cash used (since last report) | 78.39 mm | 102.01 mm | 182.31 mm | 213.51 mm | 74.99 mm | 107.00 mm |
Cash remaining | -70.59 mm | -94.21 mm | -174.51 mm | -205.71 mm | -67.18 mm | -99.19 mm |
Runway (months of cash) | -19.5 | -20.0 | -20.7 | -20.8 | -19.4 | -20.0 |
Institutional ownership, Q2 2022
48.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 49 |
Opened positions | 6 |
Closed positions | 14 |
Increased positions | 12 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 15.93 mm |
Total shares | 24.11 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
NEA Management | 6.64 mm | $3.99 mm |
Avidity Partners Management | 4.41 mm | $2.64 mm |
Rock Springs Capital Management | 2.77 mm | $1.67 mm |
Vanguard | 1.81 mm | $1.09 mm |
MAI Capital Management | 1.71 mm | $1.03 mm |
JNJ Johnson & Johnson | 1.61 mm | $964.00 k |
CHI Advisors | 750.00 k | $450.00 k |
Rosalind Advisors | 707.47 k | $1.85 mm |
BLK Blackrock | 684.20 k | $411.00 k |
SF Stifel Financial | 439.27 k | $264.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 May 23 | Nancy J Hutson | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,750 | 0.00 | 37,510 |
19 May 23 | Nancy J Hutson | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,750 | 0.00 | 0 |
19 May 23 | Loewy Caroline M | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,750 | 0.00 | 3,750 |
19 May 23 | Loewy Caroline M | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,750 | 0.00 | 0 |
19 May 23 | William D. Humphries | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,538 | 0.00 | 2,538 |
19 May 23 | William D. Humphries | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,538 | 0.00 | 0 |
19 May 23 | Thorp Clay | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,750 | 0.00 | 36,693 |
19 May 23 | Thorp Clay | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | 3,750 | 0.00 | 0 |
19 May 23 | Harrigan Edmund | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,750 | 0.00 | 9,750 |
19 May 23 | Harrigan Edmund | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | 3,750 | 0.00 | 0 |